Ocular Therapeutix Inc. Stock
€8.25
Your prediction
Ocular Therapeutix Inc. Stock
Pros and Cons of Ocular Therapeutix Inc. in the next few years
Pros
Cons
Performance of Ocular Therapeutix Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ocular Therapeutix Inc. | -0.600% | 9.272% | 14.583% | 13.699% | -21.690% | 87.756% | -27.632% |
| Lantheus Holdings Inc | 0.780% | 0.666% | 13.375% | 31.717% | 58.566% | 10.529% | - |
| Cryolife Inc. | 0.540% | 5.085% | -8.824% | -26.772% | -52.369% | 31.915% | -23.140% |
| Natera Inc | 0.810% | 6.544% | 22.142% | 35.503% | 2.487% | 338.913% | 132.069% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When delving into the financials of Ocular (NASDAQ: OCUL) in the healthcare equipment and supplies industry, the analysis reveals a company facing significant challenges, evidenced by a bleak profitability outlook and a troubling balance sheet. The indicators present a mixed scenario, where potential exists amidst considerable financial hurdles.
Market Capitalization: Ocular holds a market capitalization of approximately $1.21 billion. This sizeable market cap suggests that the company has gained investor confidence, likely due to prospects in the healthcare domain, which can often provide robust growth opportunities.
Revenue Growth: There is a notable quarterly revenue growth year-over-year (YOY) of 10.5%. This figure indicates a positive trajectory, suggesting that the company's sales efforts and product reception in the market are gaining traction. Moreover, the total revenue reported was around $59.84 million, which, despite being modest, shows movement in the right direction.
Comments
News
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Ocular Therapeutix (NASDAQ:OCUL) and Prime Medicine (NASDAQ:PRME) represent two distinct paths within the high-risk, high-reward world of medical innovation. Choosing between them requires balancing
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
According to the SEC filing dated May 15, Acuta Capital Partners, LLC disclosed a first-quarter sale of 460,887 shares of Ocular Therapeutix (NASDAQ:OCUL).
Ocular Therapeutix is a biopharmaceutical
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C
